The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Open accessAbstract
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by our group (9, 17-20) and others (7, 21, 22) have demonstrated a strong relationship between triglyceride content in liver and muscle and insulin resistance in these tissues.”
From Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (2002) · cites this paper as [9]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Thiazolidinediones, which are potent PPARγ agonists, can effectively reduce hepatic steatosis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Moreover, reductions in intracellular diacylglycerol content account for the improvements in insulin sensitivity after weight loss81 and therapy with thiazolidinediones.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“The TZDs improve insulin resistance by increasing glucose disposal in muscle and decreasing hepatic glucose output.26”
From A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (2004) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citationDENSITOMETRIC ANALYSIS OF BODY COMPOSITION: REVISION OF SOME QUANTITATIVE ASSUMPTIONS*
Brožek, J., Grande, F., Anderson, J. T., & Keys, A. B. (1963) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1963.tb17079.x · Cited by 2,263
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Self-citationDresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Self-citationGriffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Self-citationKrssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Shulman, G. I., & Roden, M. (1999) · Diabetologia · doi:10.1007/s001250051123 · Cited by 1,264
Self-citation
Cited by
Sorted by citations
Items 201–300 of 643
Jornayvaz, F. R., Lee, H., Jurczak, M. J., Alves, T. C., Guebre‐Egziabher, F., Guigni, B. A., Zhang, D., Samuel, V. T., Silva, J. E., & Shulman, G. I. (2011) · Endocrinology · doi:10.1210/en.2011-1793 · Cited by 76
Self-citationThe metabolic syndrome: an emerging health epidemic in women
Steinbaum, S. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2003.08.005 · Cited by 75
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Yoon, H. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i11.800 · Cited by 75
Ramful‐Baboolall, D., Tarnus, E., Rondeau, P., Silva, C. R. D., Bahorun, T., & Bourdon, E. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf102762s · Cited by 74
PPARγ as a metabolic regulator: insights from genomics and pharmacology
Savage, D. B. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405008793 · Cited by 75
Kim, J. K., Kim, H., Park, S., Cederberg, A., Westergren, R., Nilsson, D., Higashimori, T., Cho, Y.-R., Liu, Z., Dong, J., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1657 · Cited by 75
Self-citationSon, S. M., Song, H., Byun, J., Park, K. S., Jang, H. C., Park, Y. J., & Mook‐Jung, I. (2012) · Diabetes · doi:10.2337/db11-1735 · Cited by 81
Combined Thiazolidinedione-Insulin Therapy
Scheen, A. J. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00002 · Cited by 73
Diabetes: mellitus or lipidus?
Shafrir, E., & Raz, I. (2003) · Diabetologia · doi:10.1007/s00125-003-1052-5 · Cited by 75
Phillips, S. A., Choe, C. C., Ciaraldi, T. P., Greenberg, A. S., Kong, A. P. S., Baxi, S. C., Christiansen, L., Mudaliar, S. R. D., & Henry, R. R. (2005) · Obesity Research · doi:10.1038/oby.2005.160 · Cited by 72
Controversies surrounding the clinical potential of cinnamon for the management of diabetes
Rafehi, H., Ververis, K., & Karagiannis, T. C. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01538.x · Cited by 72
Pfützner, A., Schöndorf, T., Seidel, D., Winkler, K., Matthaei, S., Hamann, A., & Forst, T. M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.06.021 · Cited by 70
Thiazolidinediones ? some recent developments
Stümvoll, M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1179 · Cited by 71
Weissman, P. N., Goldstein, B. J., Rosenstock, J., Waterhouse, B. R., Cobitz, A. R., Wooddell, M. J., & Strow, L. J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74844 · Cited by 71
Yki‐Järvinen, H., Sutinen, J., Silveira, A. M. V., Korsheninnikova, E., Fisher, R. M., Kannisto, K., Ehrenborg, E., Eriksson, P. O., & Hamsten, A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000062885.61917.a5 · Cited by 71
Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Strowig, S. M., Avilés-Santa, L. M., & Raskin, P. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1577 · Cited by 70
Glintborg, D., Frystyk, J., Højlund, K., Andersen, K. K., Henriksen, J. E., Hermann, A. P., Hagen, C., Flyvbjerg, A., & Andersen, M. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03015.x · Cited by 69
Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease
Harrison, S. A., & Bisceglie, A. M. D. (2003) · Drugs · doi:10.2165/00003495-200363220-00001 · Cited by 69
Krssak, M., & Roden, M. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000021434.98627.dc · Cited by 68
Obesity and diabetes: lipids, ‘nowhere to run to'
Hill, M. J., Metcalfe, D., & McTernan, P. G. (2008) · Clinical Science · doi:10.1042/cs20080050 · Cited by 69
Glintborg, D., Hermann, A. P., Andersen, M., Hagen, C., Beck‐Nielsen, H., Veldhuis, J. D., & Henriksen, J. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.12.067 · Cited by 68
Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
Stage, T. B., Christensen, M. M. H., Jørgensen, N. R., Beck‐Nielsen, H., Brøsen, K., Gram, J., & Frost, M. (2018) · Bone · doi:10.1016/j.bone.2018.04.004 · Cited by 68
Lakkaraju, S. K., Yu, W., Raman, E. P., Hershfeld, A. V., Fang, L., Deshpande, D. A., & MacKerell, A. D. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500729k · Cited by 66
Cadoudal, T., Blouin, J., Collinet, M., Fouque, F., Tan, G. D., Loizon, E., BEALE, E. G., Frayn, K. N., Karpe, F., Vidal, H., et al. (2007) · Diabetologia · doi:10.1007/s00125-006-0560-5 · Cited by 67
Cardoso, R. C., Veiga‐Lopez, A., Moeller, J., Beckett, E. M., Pease, A. P., Keller, E., Madrigal, V., Chazenbalk, G. D., Dumesic, D. A., & Padmanabhan, V. (2015) · Endocrinology · doi:10.1210/en.2015-1565 · Cited by 67
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty
Huang, J. V., Greyson, C. R., & Schwartz, G. G. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024505 · Cited by 68
Skeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 76
Montecucco, F., Steffens, S., & Mach, F. (2008) · Mediators of Inflammation · doi:10.1155/2008/767623 · Cited by 62
Pharmacogenetic studies update in type 2 diabetes mellitus
Singh, S. T., Usman, K., & Banerjee, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i15.302 · Cited by 67
Leroyer, S., Tordjman, J., Chauvet, G., Quette, J., Chapron, C., Forest, C. D., & Antoine, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512943200 · Cited by 65
Sources of hepatic triglyceride accumulation during high‐fat feeding in the healthy rat
Delgado, T. C., Pinheiro, D., Caldeira, M. M., Castro, M. M. C. A., Geraldes, C. F. G. C., López‐Larrubia, P., Cerdán, S., & Jones, J. G. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1327 · Cited by 64
Ren, T., He, J., Jiang, H., Zu, L., Pu, S., Guo, X., & Xu, G. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.02061 · Cited by 63
Review article: drug therapy for non‐alcoholic fatty liver disease
Comar, K. M., & Sterling, R. K. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02751.x · Cited by 65
Hockings, P. D., Changani, K. K., Saeed, N., Reid, D. G., Birmingham, J. M., O'Brien, P. J., Osborne, J. A., Toseland, C. D. N., & Buckingham, R. E. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00268.x · Cited by 63
Iozzo, P., Hällsten, K., Oikonen, V., Virtanen, K. A., Parkkola, R. K., Kemppainen, J., Solin, O. H., Lönnqvist, F., Ferrannini, E., Knuuti, J. M., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2069 · Cited by 64
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63
β-Cell rejuvenation with thiazolidinediones
Bell, D. S. H. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.010 · Cited by 63
Juhl, C. B., Hollingdal, M., Pørksen, N. K., Prange, Å., Lönnqvist, F., & Schmitz, O. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021181 · Cited by 63
Intestinal fatty acid binding protein regulates mitochondrion β-oxidation and cholesterol uptake
Montoudis, A., Seidman, E. G., Boudreau, F., Beaulieu, J., Ménard, D., Elchebly, M., Mailhot, G., Sané, A. T., Lambert, M. A., DELVIN, E. E., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700363-jlr200 · Cited by 62
Effects of Pioglitazone on Suppressor of Cytokine Signaling 3 Expression
Kanatani, Y., Usui, I., Ishizuka, K., Bukhari, A., Fujisaka, S., Urakaze, M., Haruta, T., Kishimoto, T., Naka, T., & Kobayashi, M. (2007) · Diabetes · doi:10.2337/db06-1039 · Cited by 63
Soo, B., Ciaraldi, T. P., Park, K. S., Carter, L., Mudaliar, S. R. D., & Henry, R. R. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00141.2004 · Cited by 61
Smith, S. (2003) · Biochimie · doi:10.1016/j.biochi.2003.10.010 · Cited by 62
Sun, X., Han, R., Wang, Z., & Chen, Y. (2006) · Diabetologia · doi:10.1007/s00125-006-0228-1 · Cited by 60
Lessard, S. J., Giudice, S. L. L., Lau, W. A. K., Reid, J. J., Turner, N. A., Febbraio, M. A., Hawley, J. A., & Watt, M. J. (2004) · Endocrinology · doi:10.1210/en.2004-0659 · Cited by 61
Thiazolidinediones and the liver in humans
Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 60
Voytovich, M. H., Simonsen, C., Jenssen, T. G., Hjelmesaeth, J. S., Åsberg, A., & Hartmann, A. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh641 · Cited by 59
Todd, M. K., Watt, M. J., Le, J., Hevener, A. L., & Turcotte, L. P. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00080.2006 · Cited by 58
Rovito, D., Gionfriddo, G., Barone, I., Giordano, C., Grande, F., Amicis, F. D., Lanzino, M., Catalano, S., Andò, S., & Bonofiglio, D. (2016) · Oncotarget · doi:10.18632/oncotarget.11371 · Cited by 58
DiNicolantonio, J. J., McCarty, M. F., & O’Keefe, J. H. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 59
Lewis, G. F., Naples, M., Uffelman, K. D., Leung, N. M., Szeto, L., & Adeli, K. (2004) · Endocrinology · doi:10.1210/en.2003-1559 · Cited by 56
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
Åhrén, B., Foley, J. E., & Bosi, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01321.x · Cited by 56
Regulation of net hepatic glycogenolysis and gluconeogenesis by epinephrine in humans
Dufour, S., Lebon, V., Shulman, G. I., & Petersen, K. F. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00222.2009 · Cited by 56
Self-citationInsulin resistance: From predisposing factor to therapeutic target in type 2 diabetes
Henry, R. R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80242-4 · Cited by 55
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 57
PPAR ligands: Potential therapies for metabolic syndrome
Akiyama, T. E., Meinke, P. T., & Berger, J. P. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0067-3 · Cited by 54
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale, S. E. (2009) · Frontiers in bioscience · doi:10.2741/3301 · Cited by 55
Evans, J. L., Lin, J., & Goldfine, I. D. (2005) · Current Diabetes Reviews · doi:10.2174/157339905774574365 · Cited by 56
Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, I., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.02.005 · Cited by 55
Nonalcoholic Fatty Liver Disease
Inzucchi, S. E., Petersen, K. F., & Shulman, G. I. (2002) · New England Journal of Medicine · doi:10.1056/nejm200209053471018 · Cited by 55
Self-citationA glimpse of the connection between PPARγ and macrophage
Yu, L., Gao, Y., Aaron, N., & Qiang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1254317 · Cited by 61
Krššák, M., Hofer, H., Wrba, F., Meyerspeer, M., Brehm, A., Lohninger, A., Steindl‐Munda, P., Moser, E., Ferenci, P., & Roden, M. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.03.062 · Cited by 54
Shadid, S., & Jensen, M. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1053/s1542-3565(03)00198-8 · Cited by 52
Smith, S. A., Porter, L. E., Biswas, N., & Freed, M. I. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0705 · Cited by 54
Progress with thiazolidinediones in the management of type 2 diabetes mellitus
Meriden, T. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90017-3 · Cited by 54
Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease
Schultz, A., Mendonca, L. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2010) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.08.019 · Cited by 52
Yang, X., Wang, Q., Pang, Z.-R., Pan, M.-R., & Zhang, W. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1278454 · Cited by 53
Shen, Q., Cline, G. W., Shulman, G. I., Leibowitz, M. D., & Davies, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311729200 · Cited by 53
Self-citationLee (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000412 · Cited by 52
Kerényi, Z., Samer, H., James, R., Yan, Y., & Stewart, M. W. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.09.009 · Cited by 52
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 52
Pathway Analysis for Drug Repositioning Based on Public Database Mining
Pan, Y., Cheng, T., Wang, Y., & Bryant, S. H. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci4005354 · Cited by 51
Muurling, M., Mensink, R. P., Pijl, H., Romijn, J. A., Havekes, L. M., & Voshol, P. J. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00109-4 · Cited by 51
Jones, S. P., Janneh, O., Back, D. J., & Pirmohamed, M. (2005) · Antiviral Therapy · doi:10.1177/135965350501000202 · Cited by 51
Sutinen, J., Kannisto, K., Korsheninnikova, E., Fisher, R. M., Ehrenborg, E., Nyman, T., Virkamäki, A., Funahashi, T., Matsuzawa, Y., Vidal, H., et al. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00490.2003 · Cited by 51
Metabolic and Molecular Mechanisms of Macrophage Polarisation and Adipose Tissue Insulin Resistance
Orliaguet, L., Ejlalmanesh, T., & Alzaïd, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165731 · Cited by 53
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1518 · Cited by 50
Muscle lipid metabolism in the metabolic syndrome
Perseghin, G. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174401.07056.56 · Cited by 50
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
Lebovitz, H. E. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02557-2 · Cited by 51
Lahrita, L., Kato, E., & Kawabata, J. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.03.082 · Cited by 49
Magnetic Resonance Spectroscopy Studies of Human Metabolism
Befroy, D. E., & Shulman, G. I. (2011) · Diabetes · doi:10.2337/db09-0916 · Cited by 50
Self-citationCai, C., Qian, L., Jiang, S., Sun, Y., Wang, Q., Ma, D., Xiao, G., Li, B., Xie, S., Gao, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16822 · Cited by 51
Gene expression profiling of potential PPARγ target genes in mouse aorta
Keen, H. L., Ryan, M. J., Beyer, A., Mathur, S. N., Scheetz, T. E., Gackle, B. D., Faraci, F. M., Casavant, T. L., & Sigmund, C. D. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00027.2004 · Cited by 49
Fluid retention mediated by renal PPARγ
Staels, B. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.08.001 · Cited by 49
Assy, N. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i27.4369 · Cited by 48
New Mechanism of Rosiglitazone to Reduce Neointimal Hyperplasia
Lee, C.-S., Kwon, Y., Yang, H., Kim, S. H., Kim, T.-Y., Hur, J., Park, K. W., Cho, H.-J., Kang, H., Park, Y.-B., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.176230 · Cited by 47
The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease
Akyüz, F., Demır, K., Özdil, S., Aksoy, N., Poturoğlu, Ş., İbrişim, D., Kaymakoğlu, S., Besisik, F. S., Boztaş, G., Çakaloğlu, Y., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9145-x · Cited by 46
Kim, H., Haluzı́k, M., Gavrilova, O., Yakar, S., Portas, J., Sun, H., Pajvani, U. B., Scherer, P. E., & LeRoith, D. (2004) · Diabetologia · doi:10.1007/s00125-004-1581-6 · Cited by 47
Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update
Katsiki, N., & Hatzitolios, A. I. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833e1264 · Cited by 45
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis
Khoo, N. K. H., Fazzari, M., Chartoumpekis, D. V., Li, L., Guimarães, D. A., Arteel, G. E., Shiva, S., & Freeman, B. Α. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101132 · Cited by 46
Peters, A. L., Kendall, D. M., Buse, J. B., Boyle, P. J., Marchetti, A. E., & Lau, H. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125002937 · Cited by 45
Hausman, G., Poulos, S. P., Pringle, T. D., & Azain, M. J. (2008) · Journal of Animal Science · doi:10.2527/jas.2007-0219 · Cited by 44
Crossland, H., Constantin‐Teodosiu, D., & Greenhaff, P. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189775 · Cited by 45
Rabøl, R., Boushel, R., Almdal, T., HANSEN, C. N., Ploug, T., Haugaard, S. B., Prats, C., Madsbad, S., & Dela, F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01237.x · Cited by 45
Sun, K., Park, J., Kim, M., & Scherer, P. E. (2016) · Diabetologia · doi:10.1007/s00125-016-4130-1 · Cited by 45
Prevention of type 2 diabetes through prediabetes remission without weight loss
Sandforth, A., Arreola, E. V., Hanson, R. L., Albrechtsen, N. J. W., Holst, J. J., Ahrends, R., Coman, C., Gerst, F., Lorza‐Gil, E., Cheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03944-9 · Cited by 47
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43
Laplante, M., Festuccia, W. T., Soucy, G., Blanchard, P.-G., Renaud, A., Berger, J. P., Olivecrona, G., & Deshaies, Y. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90552.2008 · Cited by 44
Meikle, P. J., Mundra, P. A., Wong, G., Rahman, K., Huynh, K., Barlow, C. K., Duly, A. M. P., Haber, P., Whitfield, J. B., & Seth, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130346 · Cited by 43
Iso-α-acids, bitter components of beer, prevent obesity-induced cognitive decline
Ayabe, T., Ohya, R., Kondô, K., & Ano, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-23213-9 · Cited by 43
Glintborg, D., Støving, R. K., Hagen, C., Hermann, A. P., Frystyk, J., Veldhuis, J. D., Flyvbjerg, A., & Andersen, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0615 · Cited by 43
Metadata
- Authors
- Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F.
- Affiliations
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 797-802
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2995527
- OpenAlex
- W2100514340
- Cited by
- 647
- References
- 53
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 11 · 2023: 15 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 20 · 2018: 12 · 2017: 15 · 2016: 15 · 2015: 22 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 24.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- Deutsches Krebsforschungszentrum
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01DK049230, R01 DK-49230, K23DK002734, P30DK045735)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- rosiglitazone, thiazolidinediones, type 2 diabetes, insulin sensitivity, hepatic triglyceride content, extramyocellular lipids, plasma fatty acids, hyperinsulinemic-euglycemic clamp, microdialysis, lipid redistribution
- MeSH terms
- Rosiglitazone, Adipose Tissue, Blood Glucose, Body Composition, Calorimetry, Indirect, Diabetes Mellitus, Type 2, Fatty Acids, Glycerol, Glycated Hemoglobin, Humans, Hyperinsulinism, Insulin, Kinetics, Lipids, Lipolysis, Liver, Middle Aged, Magnetic Resonance Spectroscopy, Oxidation-Reduction, Thiazoles, Triglycerides, Glucose Clamp Technique, Microdialysis, Adipocytes, Muscle, Skeletal, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
